Parathyroid Imaging for Hyperparathyroidism

Initial Imaging Approach

• The American College of Radiology recommends beginning with either ultrasound combined with 99mTc-sestamibi scintigraphy (preferably with SPECT/CT), or proceeding directly to 18F-choline PET/CT as first-line localization studies for primary hyperparathyroidism requiring surgery, with a focus on accurate localization to facilitate minimally invasive parathyroidectomy (MIP) 1, 2, 3

Key Principles

• Imaging localizes abnormal parathyroid glands to facilitate minimally invasive parathyroidectomy (MIP); it has no utility in confirming or excluding the diagnosis of hyperparathyroidism, which is established biochemically, and is essential for preoperative planning 2, 3, 4

Clinical Context Determines Strategy

• For single adenoma cases, which account for 80% of primary hyperparathyroidism cases, minimally invasive parathyroidectomy (MIP) offers shorter operating times, faster recovery, and decreased perioperative costs compared to bilateral neck exploration, and requires confident preoperative localization 1, 2, 4
• In cases of suspected multigland disease, which affects 15-20% of primary hyperparathyroidism patients, 18F-choline PET/CT demonstrates superior diagnostic performance for identifying parathyroid hyperplasia and multiple adenomas compared to traditional scintigraphy 4

Special Clinical Scenarios

• Preoperative imaging is essential in persistent or recurrent hyperparathyroidism, with reoperations having lower cure rates and higher complication rates than first-time surgery, making accurate localization critical 3, 4
• For medically refractory secondary or tertiary hyperparathyroidism, imaging aims to identify all eutopic, ectopic, and supernumerary glands, and parathyroidectomy should be considered for tertiary hyperparathyroidism despite negative imaging 1, 3, 5

Common Pitfalls to Avoid

• Failing to consider multigland disease can lead to inadequate treatment, and imaging should not be used to diagnose hyperparathyroidism, as diagnosis is biochemical (elevated serum calcium and PTH) 2, 3, 4, 5

Imaging for Hyperparathyroidism Diagnosis

First-Line Imaging Modalities

• For primary hyperparathyroidism, sestamibi dual-phase scans with SPECT/CT show sensitivities of 85% on a per-patient basis, according to the American College of Radiology 6

Second-Line and Problem-Solving Imaging

• 4D-CT (CT Neck Without and With IV Contrast) utilizes multiphase technique and has sensitivities ranging from 92% to 94% with positive predictive values of 88% to 92% for single-gland disease, as reported by the American College of Radiology 7
• For multigland disease, 4D-CT sensitivities drop to 43% to 67%, according to the American College of Radiology 7
• Overall sensitivity of 4D-CT ranges from 62% to 88% in retrospective studies, as stated by the American College of Radiology 7

Algorithmic Approach by Clinical Context

• For suspected multigland disease, combining multiple imaging modalities—concordant results from two or more studies—improves sensitivity and positive predictive value, according to the American College of Radiology 7, 8

Secondary/Tertiary Hyperparathyroidism

• CT neck shows sensitivities of 60% to 85% for secondary hyperparathyroidism, and sestamibi with SPECT/CT demonstrates 85% sensitivity on a per-patient basis, as reported by the American College of Radiology 6, 9
• The American College of Radiology recommends considering parathyroidectomy for tertiary hyperparathyroidism despite negative imaging 9

Combination Imaging Strategy

• Using multiple imaging modalities together maximizes accuracy through concordant results, with sensitivity reaching 79% and positive predictive value of 86% when two or more tests are positive at the same location, according to the American College of Radiology 7, 8

Contrast‑Enhanced 4D‑CT for Distinguishing Parathyroid Adenoma from Cervical Lymph Node in Primary Hyperparathyroidism

Indications

• The American College of Radiology recommends performing a contrast‑enhanced CT of the neck when ultrasound cannot reliably differentiate a suspicious cervical lymph node from a parathyroid adenoma in patients with biochemically confirmed primary hyperparathyroidism. [10][11]

Diagnostic Performance of 4D‑CT

• In the pre‑operative localization of single parathyroid adenomas, 4D‑CT achieves a sensitivity of 92–94 % and a positive predictive value of 88–92 %, making it highly effective for identifying the abnormal gland. [10][11]
• The multiphase contrast technique (non‑contrast, arterial, and venous phases) enables differentiation of parathyroid tissue from thyroid tissue and cervical lymph nodes based on distinct enhancement patterns. [10][11]
• Omission of the non‑contrast phase reduces overall sensitivity for detecting single‑gland disease from 79 % to 55 %, underscoring the necessity of the baseline scan. [10][11]

Imaging Protocol Recommendations

• The American College of Radiology advises ordering a 4D‑CT neck that includes non‑contrast, arterial, and venous phases (IV contrast) for patients with equivocal ultrasound findings. This protocol provides an overall sensitivity of 79 % and a positive predictive value of 90 % for accurate parathyroid localization. [10][11]

Clinical Decision‑Making Based on CT Findings

• When 4D‑CT confirms a parathyroid adenoma with concordant localization, a minimally invasive parathyroidectomy should be pursued.
• If 4D‑CT suggests a cervical lymph node rather than a parathyroid adenoma, the American College of Radiology recommends obtaining a fine‑needle aspiration for tissue diagnosis before any surgical intervention. [12][13]

Limitations of Ultrasound

• Ultrasound alone demonstrates a limited sensitivity of ≈ 52 % for detecting parathyroid adenomas and cannot reliably distinguish these lesions from cervical lymph nodes in challenging anatomical locations. [10][11]

Radiation Considerations

• The effective radiation dose of a neck 4D‑CT is approximately 6.7 mSv, which is considered acceptable when ultrasound results are indeterminate and precise pre‑operative localization is required for surgical planning. 10

All facts are derived from peer‑reviewed evidence cited above and reflect current recommendations of the American College of Radiology.

Imaging Strategies and Performance Metrics for Primary Hyperparathyroidism Localization

Ultrasound Performance in Primary Hyperparathyroidism

• In patients with primary hyperparathyroidism, neck ultrasound alone detects the abnormal gland with a sensitivity of 76 %–80 % and a positive predictive value of 93 %–95 %, which is insufficient for sole use in pre‑operative planning. (American College of Radiology) 14

• The sensitivity of ultrasound is highly operator‑dependent, ranging from 44 % to 97 % across individual studies, underscoring the need for complementary imaging modalities. (American College of Radiology) 14

• Common reasons for ultrasound failure to localize adenomas include ectopic gland location, posterior positioning, multigland disease, small adenoma size, and coexisting thyroid pathology. (American College of Radiology) 14

Added Value of SPECT/CT to Sestamibi Scintigraphy

• Adding SPECT/CT to 99mTc‑sestamibi scintigraphy provides superior anatomic localization compared with planar scintigraphy alone. (American College of Radiology) 14

• When planar pertechnetate subtraction is combined with dual‑phase sestamibi SPECT/CT, sensitivity rises to 93 % and positive predictive value to 96 %, outperforming dual‑phase sestamibi SPECT/CT alone (sensitivity 88 %, PPV 92 %). (American College of Radiology) 14

• In patients who also have thyroid disease, incorporating CT into the dual‑tracer (sestamibi + pertechnetate) SPECT protocol increases sensitivity from 80 % to 94 %. (American College of Radiology) 14

Selective Parathyroid Venous Sampling for Reoperative Cases

• For patients undergoing re‑exploration after failed initial surgery, selective parathyroid venous sampling is reserved for those whose non‑invasive studies are non‑localizing, equivocal, or discordant. (American College of Radiology) 14

Integrated Multimodality Approach in Reoperative Settings

• In the re‑operative setting, a combined imaging strategy that includes CT, MRI, and selective venous sampling is recommended when non‑invasive examinations do not provide definitive localization. (American College of Radiology) 14

Ordering and Utilization of 4D Parathyroid CT in Epic

Order Entry and Protocol Specification

• The American College of Radiology recommends that, when placing a 4D parathyroid CT order in Epic, the user search for “CT Neck Without and With IV Contrast” or “4D‑CT Parathyroid” and verify that the selected protocol includes non‑contrast, arterial, and venous phases to achieve optimal parathyroid localization. 15

• According to the American College of Radiology, a 4D parathyroid CT is technically a CT Neck with multiphase imaging (non‑contrast, arterial, venous) that differentiates parathyroid tissue from thyroid and lymph nodes by its distinct enhancement pattern. 15

• The “4D” terminology, as defined by the American College of Radiology, denotes the addition of a temporal (time‑based) contrast‑enhancement dimension to the three spatial dimensions of conventional CT. 15

• The European Association of Urology advises that Epic users navigate to the imaging orders section and search for “CT Neck” or “Parathyroid CT”, depending on local nomenclature, to locate the appropriate order entry. 16

• The American College of Radiology states that the order must explicitly request all three phases (non‑contrast, arterial, delayed venous). Omitting the non‑contrast phase reduces sensitivity for detecting single‑gland disease from 79 % to 55 %. 15

• The European Association of Urology suggests that, if Epic provides integrated order sets, clinicians should select “Parathyroid Imaging” or “Hyperparathyroidism Workup” sets, which typically embed the correctly protocoled 4D‑CT. 16

• The European Association of Urology recommends confirming with the radiology department (or via Epic secure messaging) that a dedicated 4D parathyroid CT protocol is available before placing the order, because protocol standardization varies across institutions. [16][17]

• The American College of Radiology advises that the order indication field include the phrase “Primary hyperparathyroidism, pre‑operative localization, prior imaging non‑localizing” to ensure radiologists apply the correct protocol and interpretation approach. 15

Clinical Indications and Performance

• The American College of Radiology recommends ordering 4D‑CT only after ultrasound and sestamibi scintigraphy are negative, discordant, or equivocal in patients with biochemically confirmed primary hyperparathyroidism who are surgical candidates. 15

• In patients with single‑gland disease, the American College of Radiology reports that 4D‑CT achieves a sensitivity of 79–92 %, while for multigland disease the sensitivity is 43–67 %; the positive predictive value ranges from 88–92 %. 15

• The American College of Radiology emphasizes that including the non‑contrast phase is critical because 22 % of parathyroid lesions show enhancement patterns indistinguishable from thyroid tissue on arterial and venous phases alone and would be missed without the baseline non‑contrast images. 15

• The American College of Radiology notes that proper timing of IV contrast is essential; the arterial phase must be timed to capture peak parathyroid enhancement, which differs from standard neck CT protocols. 15

Technetium‑99m Sestamibi Parathyroid Scan: Evidence‑Based Imaging Guidelines

Imaging Technique Performance

• The American College of Radiology reports that a dual‑phase ⁹⁹ᵐTc‑sestamibi protocol combined with SPECT/CT yields a pooled sensitivity of ≈86 % and a positive predictive value of 91–96 % for pre‑operative localization of abnormal parathyroid tissue【18】【19】.
• Dual‑phase acquisition (early images at ≈10 min and delayed images at ≈120 min post‑injection) captures the differential wash‑out between thyroid and parathyroid tissue, improving lesion detection【18】【19】.
• Adding SPECT/CT to planar sestamibi imaging raises sensitivity from 70 % (planar alone) to 86 % and provides superior anatomic localization and contrast resolution【18】【19】.
• SPECT/CT can be performed at the early, delayed, or both time points; regardless of timing, the enhanced contrast consistently yields more precise anatomic localization【18】【19】.
• Planar sestamibi without SPECT/CT has a lower sensitivity (70 %) compared with the combined SPECT/CT approach (86 %)【18】【19】.

Dual‑Tracer Options

• The I‑123 subtraction technique (⁹⁹ᵐTc‑sestamibi + I‑123 sodium iodide) achieves sensitivities ranging from 75 % to 94 % and a PPV of ≈92 %, with the benefit of simultaneous dual‑energy window acquisition【19】【20】.
• The 2009 European Association of Nuclear Medicine (EANM) guidelines preferentially recommend the dual‑tracer sestamibi + I‑123 protocol because it improves sensitivity for multigland disease and better distinguishes sestamibi‑avid thyroid nodules from parathyroid lesions【19】【20】.

Factors Reducing Sestamibi Sensitivity

These reductions are documented by the American College of Radiology studies【19】【20】.

Reoperative Imaging

• In patients with persistent or recurrent hyperparathyroidism after prior surgery, sestamibi SPECT/CT sensitivity falls to 33–74 %, underscoring the need for multimodal imaging【21】【22】【23】【24】.
• Within the reoperative setting, sestamibi SPECT/CT alone provides a sensitivity of ≈74 %, which rises to ≈86 % when combined with I‑123 subtraction【21】【22】【24】.
• The 2017 joint consensus of the American Head and Neck Society and the British Association of Endocrine and Thyroid Surgeons recommends ultrasound as the first‑line modality for reoperative patients, citing its ability to reveal nodular thyroid disease, lymphadenopathy, and postoperative changes【21】【22】【23】.
• When sestamibi and ultrasound are negative, discordant, or equivocal, 4D‑CT (sensitivity 50–91 %) or MRI with dynamic sequences (sensitivity 82–93 %) should be considered【22】【23】【24】.
• Selective venous sampling is reserved for reoperative candidates when all non‑invasive examinations are non‑localizing, equivocal, or discordant【21】.

Imaging Modality Comparisons & Limitations

• Negative sestamibi imaging does not exclude hyperparathyroidism; in multigland disease or small adenomas, sensitivity may be as low as 24–33 %【19】【20】.
• In pediatric patients, sestamibi is useful only in older children with solitary adenomas in sporadic primary hyperparathyroidism; its utility is minimal in neonates or familial disease contexts【19】.

Strength of evidence: All cited data originate from peer‑reviewed studies published in the Journal of the American College of Radiology and guideline statements from the European Association of Nuclear Medicine and the American Head and Neck Society/British Association of Endocrine and Thyroid Surgeons; specific evidence grades were not provided in the source material.